Scientists hail machine which keeps liver ‘alive' outside body pre-transplant
A machine which keeps a liver “alive” outside the body for up to 24 hours before a transplant could have a “transformative effect” on organ waiting lists, scientists have said.
The normothermic machine perfusion process maintains the liver at body temperature, supplying it with oxygenated blood, medication and nutrients – similar to a patient on life support.
When compared to a standard technique, it increased the number of livers suitable for transplant, preserved them for longer and reduced the amount of injury to the organ, according to research published in the journal Nature.
Livers are conventionally kept cold in an ice box as they are transported to the patient for transplant, which can cause damage.
A study of 220 liver transplant patients – the first randomised controlled trial to compare normothermic machine perfusion with cold storage in human liver transplants – found the method led to a 50% reduction in graft injuries.
There was also a 54% increase in the mean duration over which livers were preserved and a 50% lower rate of organ discard, according to the study.
This meant 20% more livers were transplanted, which researchers hope will be replicated in a clinical setting.
Lead author David Nasralla, from the Nuffield Department of Surgical Sciences at the University of Oxford, told the Press Association: “The biggest challenge facing liver transplantation around the world is the desperate shortage of donor organs, with approximately one in five patients in the UK dying whilst waiting for a liver transplant.
“In our study, not only have we shown that livers preserved using normothermic machine perfusion have better outcomes after transplantation, but also that these findings were achieved in the context of better organ utilisation and longer preservation when compared to conventional cold storage in an ice box.
“If these findings can be translated into clinical practice it could have a transformative effect on transplant waiting list mortality around the world.”
Many potential donor organs cannot currently be used because “sub-optimal” livers do not react well to cold storage.
Surgeons also have no reliable way of testing if they will work properly before the transplant.
However the machine, the result of more than 20 years of development, is able to perform tests to see how well a liver would function after transplant.
While the trial only examined livers which would be deemed suitable for transplant under standard practice, the technology could allow surgeons to consider a wider pool of donor organs.
This could lead to the use of organs currently considered “untransplantable” and increase the number available for those on the waiting list, the researchers said.
The authors concluded: “This study describes the formal clinical evaluation of a novel technology in liver transplantation, and could herald the start of a new era of intervention during organ preservation.
“It represents a first, necessary step in demonstrating that normothermic machine perfusion is feasible, safe and effective in clinical practice; the fact that the study has definitively met its primary endpoint should now enable the exploration of the technology’s wider potential.”